TABLE 2.
Molecular correction with multiple algorithms from reanalysis of clinical trial data from Rwanda (a high-transmission study site) and Cambodia (a low-transmission site)a
| Country | Drugs testedb | Classification of recurrent infection | No. of infections classified by algorithm |
|||
|---|---|---|---|---|---|---|
| WHO/MMV | No glurp | ≥2/3 markers | Allelic family switch | |||
| Rwanda | AR-LF | Recrudescence | 17 | 27 | 36 | 59 |
| Reinfections | 93 | 83 | 73 | 51 | ||
| DHA-PPQ | Recrudescence | 3 | 6 | 8 | 18 | |
| Reinfections | 40 | 37 | 35 | 25 | ||
| Cambodia | AS-AQ | Recrudescence | 5 | 5 | 5 | 5 |
| Reinfections | 0 | 0 | 0 | 0 | ||
| DHA-PPQ | Recrudescence | 45 | 47 | 47 | 47 | |
| Reinfections | 3 | 1 | 1 | 1 | ||
| AS-PYN | Recrudescence | 12 | 12 | 12 | 12 | |
| Reinfections | 0 | 0 | 0 | 0 | ||
a
Full details of study sites and methodology are provided in Materials and Methods.
b
AS-AQ, artesunate plus amodiaquine; DHA-PPQ, dihydroartemisinin plus piperaquine; AR-LF, artemether plus lumefantrine; AS-PYN, artesunate plus pyronaridine.